OS Therapies (OSTX) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

OSTX OS Therapies

Watchlist

3.725
-0.735-16.48%

Trading Dec 13 12:25 ET

79.11MMarket Cap-10.64P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Express News | Amex Halt Add Info Lst 3.530000
ReutersDec 12 09:30 ET
NYSE American Net Change Percentage Gainers & Losers
Dow JonesDec 11 17:41 ET
OS Therapies Analyst Ratings
BenzingaNov 26 09:53 ET · Ratings
Maxim Group Initiates OS Therapies(OSTX.US) With Buy Rating, Announces Target Price $8
Moomoo NewsNov 26 08:31 ET · Ratings
Express News | Os Therapies : Maxim Group Initiates Coverage With Buy Rating; Target Price $8
ReutersNov 26 07:38 ET
OS Therapies | 8-K: OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
SECNov 15 16:09 ET

Comments

Aukina24

23 hours ago

Where’s the volume…

$OS Therapies (OSTX.US)$

Aukina24

Dec 11 21:25

Lots of opportunities

$OS Therapies (OSTX.US)$ lots of breakthrough

Jaguar8

Sep 11 07:18

NEWS

$OS Therapies (OSTX.US)$
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
Folate receptor alpha targeting drug conjugate & hexa silanol exatecan (FRA-H) payloads tested in animal models of ovarian cancer
Strong efficacy for FRA-H in KB and IGROV-1 mouse models of ovarian cancer
Strong safety profile for FRA-H wit...

Jaguar8

Aug 29 06:53

NEWS

$OS Therapies (OSTX.US)$
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
OS Therapies Incorporated (NYSE:OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that the last patient (Patient #41) enrolled in the AOST-2121 clinical trial (NCT04974008) of OST-HER2 in recurred, resected Osteosarcoma (OS) - has received its last treatment dos...

AceChiang

Aug 22 00:54

Share Your Profit/Loss

Heat List

Overall

No Data

Investment Theme

Top Gainers Yesterday

Intraday-0.38%

Recent IPOs

Intraday-0.71%